OncoAlert

OUR COMPLETE #SABCS24 Newsletter IS OUT REGISTER at www.OncoAlert360.com OR https://buff.ly/48Xpgz0 This Includes all of OUR TOP pick of TRIALS presented during these last 4 days in San Antonio & Video Interviews from our Collaborators at Video Journal of Oncology (VJOncology) and high5md Matteo Lambertini 🇮🇹 Erika Hamilton, MD🇺🇸 Hope Rugo 🇺🇸 Janice Cowden 🇺🇸 Stephanie Graff, MD, FACP, FASCO 🇺🇸 Maryam Lustberg 🇺🇸 Diane Mapes 🇺🇸 Nadia Harbeck 🇩🇪 Dr. Javier Cortés Castán 🇪🇸 Roberta A Albany🇺🇸 Julia Maués 🇺🇸 Elisa Agostinetto 🇧🇪 Stacey Tinianov, MPH, BCPA 🇺🇸 Christine Hodgdon 🇺🇸 Eva Schumacher-Wulf🇩🇪 Icro Meattini🇮🇹 Isabel Rubio 🇪🇸 Evandro de Azambuja 🇧🇪 Philippe Aftimos MD 🇧🇪 Tanja Spanic 🇸🇮 Sara Tolaney🇺🇸 Giuseppe Curigliano 🇮🇹 Kevin Punie 🇧🇪 Elisabetta Bonzano 🇮🇹 Luca Arecco 🇮🇹 José Fernando Prado Moura 🇧🇷 Kelly Shanahan 🇺🇸 Alizée Camps--Maléa 🇫🇷 Jame Abraham, M.D. FACP 🇺🇸 Sherene Loi 🇦🇺 Tatiana Prowell, M.D.

Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography out on @NatureComms Mutations in the NRF2-KEAP1 pathway are prevalent in non-small cell #LungCancer ( #NSCLC ), contributing to therapeutic resistance and poor outcomes. This study demonstrates that positron emission tomography (PET) imaging using the system xc− radiotracer, [18F]FSPG, can non-invasively identify NRF2 activation in mouse models of NSCLC. A NRF2-related gene expression signature was also found in a large cohort of NSCLC patients, highlighting a potential for preselecting candidates for [18F]FSPG imaging. Moreover, the study identifies system xc− as a metabolic vulnerability, which can be therapeutically targeted, offering a new approach for suppressing tumor growth and addressing therapy resistance in NSCLC. https://buff.ly/41LL1jM Richard Edwards Friedrich Baark Aimee F. Janine DeBlasi Pritin Soni Oskar Vilhelmsson Timmermand Ariana Huebner Charles Swanton Robert Hynds Gina DeNicola Tim Witney

You’re invited to a FREE webinar hosted by Mirrors of Medicine Link: https://buff.ly/3ZNsgtD discussing the latest treatments and strategies for optimizing the management of (mHSPC) metastatic hormone-sensitive prostate cancer, from evidence to action. @vandamme_jvd

Risk-reducing mastectomy and salpingo-oophorectomy significantly improve overall survival, disease-free survival, and breast cancer-free interval in young BRCA-positive breast cancer patients, with a greater impact of RRSO seen in BRCA1 carriers. #BreastCancer Report with Shani Paluch-Shimon (high5 Onc)

The Phase II ELCIN trial (NCT05596409) Report with Virginia Kaklamani (VJ Onc) https://buff.ly/49NQ1Xh evaluates the efficacy and safety of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Building on the results of the EMERALD trial (NCT03778931), which showed significant progression-free survival benefits with elacestrant, the ELCIN trial aims to further validate its therapeutic potential in a similar patient population. This study focuses on how well elacestrant performs in patients who have already undergone prior treatments, with the goal of improving outcomes in advanced hormone receptor-positive, HER2-negative breast cancer.

Join our collaborators at Mirrors of Medicine for webinar 22 January 2025 from 19:00 to 20:00 CET SIGN UP HERE https://buff.ly/4f7g6Bu as experts @EtienneB66 @E_de_Azambuja Valentina Guarneri, @CristinaSaura3 and @HansWildiers discuss the management of hormone receptor-positive, HER2-negative metastatic breast cancer.

Join our collaborators at Oncobites.tv https://lnkd.in/dMTRTVkd interview featuring Cristiano de Pádua Souza as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Dr. Elisa Agostinetto from the Jules Bordet Institute in Brussels interviews Dr. Souza, discussing the safety and impact of this therapy.

 Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial out in JCO The postMONARCH trial evaluated the efficacy of switching endocrine therapy (ET) with or without continued CDK4/6 inhibition using abemaciclib in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who had progressed on prior CDK4/6 inhibitors. In this Phase III trial, 368 patients were randomized to receive either abemaciclib+fulvestrant or placebo+fulvestrant. The study found that abemaciclib+fulvestrant significantly improved progression-free survival (PFS) compared to placebo+fulvestrant, with a hazard ratio of 0.73 and a median PFS of 6.0 versus 5.3 months. The treatment benefit was consistent across clinical and genomic subgroups, including patients with ESR1 or PIK3CA mutations. Additionally, the objective response rate (ORR) was higher with abemaciclib+fulvestrant (17% vs 7%), and no new safety concerns were observed, reinforcing abemaciclib's potential as an additional therapy option in this setting. https://lnkd.in/dTabQEB6 Kevin Kalinsky Giampaolo Bianchini Erika Hamilton, MD Stephanie Graff, MD, FACP, FASCO Rinath Jeselsohn Umut Demirci Miguel Martín Rachel Layman sara hurvitz Sarah Sammons MD Joseph Lai Holly Knoderer, MD MBA MSc Cynthia Sandoval, PhD Bastien Nguyen Yanhong Zhou Elizabeth (Lisa) Ravenberg Lacey Litchfield Lillian Smyth, MD Seth Wander

Meet the Heart & Soul of the OncoAlert 🚨Network Great Oncologist/Amazing friend/Founding Faculty An amazing interview at ASCO Connection https://lnkd.in/dC_3QQpg Our dear friend Toni Choueiri 🇺🇸serves as the director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and as a professor at Harvard Medical School . A brief Preview of this interview: His passion for oncology was sparked by two young patients he encountered early in medical school, which profoundly impacted his career path. Dr. Choueiri describes oncology as a dynamic and research-driven field, where every patient's cancer behaves uniquely, demanding a fast-paced and adaptive approach to treatment. Besides his medical career, he plays an active role in American Society of Clinical Oncology (ASCO) , where he has held various leadership positions, including on the Board of Directors, chairing the virtual ASCO Plenary Series, and co-founding the ASCO International Medical Graduates Community of Practice. Outside of work, Dr. Choueiri is passionate about sports, having once dreamed of becoming a professional soccer player, and even helped organize an international soccer tournament alongside ASCO meetings. He also enjoys cooking Lebanese 🇱🇧food and shares his culinary adventures on social media. His personal philosophy, encourages him to stay focused and persistent in the face of challenges. Whether spending time with his family, biking, or participating in fundraising events like the Pan-Mass Challenge, Dr. Choueiri finds happiness both in his personal life and in his professional achievements, especially when his research brings positive outcomes for his patients. GU Faculty Sumanta Pal, MD, FASCO @cristiane bergerot @Daniel Heng Andrea Apolo Petros Grivas Tian Zhang Hans Hammers Ravindran Kanesvaran Neeraj Agarwal, MD, FASCO Prof. Dr. Axel S. Merseburger Guru Sonpavde, MD Enrique Grande Silke Gillessen Eleni Efstathiou Thomas Powles,MD @Braun MDPhD Daniel Castellano Yüksel ÜRÜN #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps--Maléa Biagio Ricciuti Emre Yekeduz Hidehito Horinouchi Fadi Haddad José Fernando Prado Moura Elisa Agostinetto Elisabetta Bonzano Bárbara Melão Dr. Joseph McCollom DO Luca Arecco

Just Out FDA 🇺🇸 approved ensartinib for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer ( #NSCLC ) 🫁who have not received prior ALK-targeted therapy. The approval was based on the eXALT3 trial, a randomized study comparing ensartinib to crizotinib in 290 patients. Ensartinib significantly improved progression-free survival (PFS) with a median of 25.8 months versus 12.7 months for crizotinib (HR 0.56, p=0.0007). However, there was no significant difference in overall survival between the two treatments. Common side effects included rash, musculoskeletal pain, and fatigue. #LungCancer https://buff.ly/4gicU7q Christian Rolfo, MD, PhD, MBA,Dr.hc GILBERTO de lima LOPES Junior Narjust Florez M.D. Stephen Liu Antonio Calles Marina Chiara Garassino Peters Solange Umberto Malapelle Giannis Mountzios Charu Agrawal Christine M. Lovly, MD, PhD, FASCO Fabrice Barlesi Janet Freeman-Daily Pilar Garrido Jill Feldman Ben SolomonVanita Noronha Jarushka Naidoo Martin Reck Julien MAZIERES Terri Conneran Hidehito Horinouchi Biagio Ricciuti